Clinical trials: Metastatic Colorectal Cancer, completed
Metastatic Colorectal Cancers, Metastatic Gastric Cancers
Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers
Prospective non randomized, non-comparative, dose escalation, two arms open phase I trial to assess the safety and tolerability of capecitabine given in combination with aflibercept in patients with measurable or evaluable…
- Conditions
- Metastatic Colorectal Cancers, Metastatic Gastric Cancers, Metastatic Oesophageal Cancers, Metastatic Pancreatic Cancers
- Trial name
- MOMENTUM1 (NCT01843725)
- Testing
- capecitabine, aflibercept
- Where
- Belgium
- Volunteers
- 37 people
- Sponsor
- Jules Bordet Institute
Advanced or Metastatic Solid Tumors, Advanced or Metastatic Colorectal Cancer (mCRC)
First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors
Study HS-CA102N-101 is a phase 1, two part (dose escalation, dose expansion), multicenter, non-randomized, open-label, multiple dose, first-in-human study of CA102N monotherapy and of CA102N combined with trifluridine/tipiracil…
- Trial name
- NCT03616574
- Testing
- CA102N, LONSURF
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Holy Stone Healthcare Co., Ltd
Metastatic Colorectal Cancer
Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies
The purpose of this study is to evaluate the efficacy of S 95005 in patients with metastatic colorectal cancer (mCRC) who are refractory or intolerant to standard chemotherapies in terms of Progression-Free Survival rate at 2…
- Trial name
- NCT03274882
- Testing
- S95005
- Where
- 2 sites in Russia
- Volunteers
- 26 people
- Sponsor
- Institut de Recherches Internationales Servier
Metastatic Adenocarcinoma of the Colon or Rectum, Malignant Solid Tumors
Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors
The purpose of the study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-MIF antibody in subjects with malignant solid tumors (Arm 1) and in subjects with metastatic adenocarcinoma of the…
- Trial name
- NCT01765790
- Testing
- Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
- Where
- 5 sites in United States, Germany
- Volunteers
- 68 people
- Sponsor
- Baxalta now part of Shire
Metastatic Colorectal Cancer
Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen
The purpose of this study is to assess the efficacy and safety of treatment with FOLFIRI-aflibercept compared to initial treatment with FOLFIRI-aflibercept (for 6 cycles) followed by maintenance with 5FU-aflibercept, in an…
- Trial name
- AFEMA (NCT03279289)
- Testing
- Aflibercept, Irinotecan, folinic acid (dl racemic)
- Where
- Spain
- Volunteers
- 170 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Colorectal Cancer
Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer
RATIONALE: Brivanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00640471
- Testing
- cetuximab, brivanib alaninate
- Where
- 37 sites in Canada
- Volunteers
- 750 people
- Sponsor
- NCIC Clinical Trials Group
Colorectal Cancer, Hepatic Metastasis
Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer
The purpose of this study is to to evaluate the correlation of overall objective response according to RECIST v1.1. criteria evaluated by conventional imaging techniques, morphologic response by CT, and histopathologic response…
- Trial name
- AVAMET (NCT01493713)
- Testing
- Evaluate the correlation of overall different objective response.
- Where
- 21 sites in Spain
- Volunteers
- 83 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Lymph Node Metastasis, Colorectal Cancer
Clinical Trial Comparing Carnoy's and GEWF Solutions
Regional lymph node metastasis is a major determinant of local recurrence and overall survival rates in patients with colorectal cancer.
- Trial name
- NCT02704988
- Testing
- Carnoy Solution, GEWF Solution
- Where
- Brazil
- Volunteers
- 181 people
- Sponsor
- Hospital Moinhos de Vento
Lymphomas, Solid Tumors
TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas
Background: Methoxyamine hydrochloride (TRC102) is a new cancer treatment drug that may help improve the results of chemotherapy.
- Conditions
- Lymphomas, Solid Tumors, NSCLC, Metastatic Colon Carcinoma
- Trial name
- NCT01851369
- Testing
- TRC102, CT scan, Lomotil
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer Metastatic
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
This randomized (2:1), multi-center, placebo-controlled, phase II efficacy study is designed to compare PFS between regorafenib + FOLFIRI chemotherapy (ARM A) versus placebo + FOLFIRI (ARM B) in patients with mCRC previously…
- Trial name
- NCT01298570
- Testing
- Regorafenib (BAY 73-4506), FOLFIRI
- Where
- 24 sites in United States, Ireland
- Volunteers
- 181 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Metastatic Colorectal Cancer
Fruquintinib DDI Study With P-gp and BCRP Substrates
Fruquintinib DDI Study with P-gp and BCRP Substrates
- Trial name
- NCT05368805
- Testing
- Fruquintinib, Dabigatran Etexilate, Rosuvastatin
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Colorectal Cancer Metastatic, C-met Overexpression
Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects
This is a single-arm, Simon 2-stage, phase 2 clinical study conducted in subjects with advanced or metastatic colorectal cancer who have previously received ≥ 1 prior line of systemic therapies and are resistant to EGFR inhibitor…
- Trial name
- NCT01892527
- Testing
- Tivantinib (ARQ197)
- Where
- Italy
- Volunteers
- 43 people
- Sponsor
- Armando Santoro, MD
Colonic Cancer, Metastasis to Lymph Node
EMI-137 in Laparoscopic Colonic Resections
EMI-137 in laparoscopic colonic resections is a single-centre stage IIa developmental study. Ten adult participants with a diagnosis of colon adenocarcinoma undergoing laparoscopic colonic will be recruited to the trial.
- Trial name
- NCT03360461
- Testing
- EMI-137
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- University of Leeds
Non-colorectal Liver Metastasis, Liver Metastasis
National Registry of Hepatic Metastases From Non-Colorectal Cancer"
The investigators designed this observational, retrospective, multicenter study including all patients who underwent surgery for non-colorectal liver metastases between January 2010 and December 2022, with the aim of establishing…
- Conditions
- Non-colorectal Liver Metastasis, Liver Metastasis, Non-neuroendocrine Liver Metastasis, Liver Metastases
- Trial name
- REMENOCOR (NCT07180641)
- Volunteers
- 1,039 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Colorectal Cancer, Colorectal Carcinoma
FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer
This study is a randomized multi-center trial that will assess the effect of adding Selective Internal Radiation Therapy (SIRT), using SIR-Spheres microspheres®, to a standard chemotherapy regimen of FOLFOX as first line therapy…
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Liver Metastases
- Trial name
- SIRFLOX (NCT00724503)
- Testing
- SIR-Spheres yttrium-90 microspheres, Systemic chemotherapy (FOLFOX)
- Where
- 111 sites in United States, Australia and 9 more
- Volunteers
- 530 people
- Sponsor
- Sirtex Medical
Colorectal Cancer
Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004042
- Testing
- monoclonal antibody F19, iodine I 131 monoclonal antibody F19
- Where
- 3 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colon Cancer
Placebo-Controlled Study of Perifosine + Single Agent Chemotherapy for Metastatic Cancer Patients
This is an exploratory phase 2, randomized placebo-controlled trial with stratification for disease and chemotherapy type. The study is subsequently closed to enrollment in all arms except patients with metastatic colorectal…
- Trial name
- NCT00398879
- Testing
- Perifosine, Capecitabine
- Where
- 49 sites in United States
- Volunteers
- 381 people
- Sponsor
- AEterna Zentaris
Colorectal Cancer
Xeloda or UFT (Tegafur-uracil) With Folinic Acid in Advanced or Metastatic Colorectal Cancer
The scope of the trial is to determine the preference of patients, after randomization and cross-over, for one of the two treatments. Another objective of the trial is to assess and compare the safety of each treatment.
- Trial name
- COLOCROSS (NCT00905047)
- Testing
- XELODA, TEGAFUR URACIL - FOLINIC ACID
- Where
- 13 sites in France
- Volunteers
- 89 people
- Sponsor
- Centre Oscar Lambret
Colorectal Cancer, Diarrhea
Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00084721
- Testing
- celecoxib, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Roswell Park Cancer Institute
Colorectal Cancer, Metastatic Cancer
Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy
The purpose of this study is to determine that panitumumab will have clinically meaningful anti-tumor activity in patients with metastatic colorectal cancer who have developed progressive disease or relapsed while on or after…
- Trial name
- NCT00083616
- Testing
- Panitumumab
- Volunteers
- 185 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.